#cardiovascular

In limited studies to date, semaglutide and other weight-loss drugs appear to be safe and effective for people living with HIV.

Some HIV meds have been linked to fatty liver disease and weight gain.

NIH-funded research sheds light on link between COVID-19 and increased risk of cardiovascular disease and stroke.

NAFLD is associated with risk factors such as obesity and inflammatory biomarkers and with events including heart attacks and strokes.

Statins reduce low-density lipoprotein (LDL) cholesterol and also have anti-inflammatory properties.

Certain drugs in this class may increase the likelihood of diabetes and hypertension, but cardiovascular risk factors can be managed.

Studies highlight the need for better prevention and management of age-related health problems.

Eating one meal a day certainly simplifies life, but is it a good idea?

Ruxolitinib might have contributed to a functional cure after a stem cell transplant without a rare mutation.

NIH’s Carl Dieffenbach and Bill Kapogiannis interview experts about research presented at IAS 2023.

Conversations on reducing cardiovascular disease among people with HIV and long-acting prevention and treatment options.

REPRIEVE trial finds pitavastatin reduced the risk for heart attack, stroke and other major cardiovascular events by 35%.

A large body of research has shown that people living with HIV are at greater risk for cardiovascular disease.

The injectable medication can reverse metabolic syndrome in some HIV-positive people with excess belly fat.

A large clinical trial found that daily multivitamins led to modest improvements in memory over a three-year period.

Among people 65 and older, cardiovascular deaths plunged 22% between 1999 and 2010 -- but then climbed 13% between 2011 and 2019.